Table A Studies evaluating pediatric education about asthma
Jenkinson et alw1 | Significant knowledge increases (P=0.002) No other significant change | |||
Staudenmayer et alw2 | Change in direction of fewer school absences (P=0.09) Reduced No of emergency physician visits for those with baseline use (P=0.03) Reduced No of hospitalisations (P=0.03) | |||
Fireman et alw3 | Decreased school absences (P<0.05) Reduced ED use (no statistical analysis) Reduced hospitalisation time (no statistical analysis) | |||
Lewis et alw4 | Reduced ED visits (P<0.001) Reduced No of hospital days (P<0.01) | |||
Hindi-Alexander and Croppw5 | Reduced school absences (P<0.005) Reduced ED use but not significant No difference in hospitalisations | |||
McNabb et alw6 | Reduced ED use (no statistical analysis) | |||
LeBaron et alw7 | Increased knowledge about cromolyn (no statistical analysis) No change in pulmonary function or systems | |||
Rubin et alw8 | No difference in school absences Improvement in ED use but not significant | |||
Clark et alw9 | Improved academic performance (P<0.05) Increased self management behaviour (parent P=0.0001, child P= 0.05) No difference in school absences Reduced ED use among those with baseline use (P=0.05) Reduced hospitalisations among those with baseline use (P=0.05) | |||
Mesters et alw10 | Higher level of asthma self efficacy (P<0.02) Increased self management behaviour (P<0.01) Decreased MD visits (P<0.01) | |||
Wilson and Starr-Schneidkrautw11 | Increased symptom free days (P=0.004) Fewer nights of parental sleep interruption | |||
Rakos et alw12 | No significant difference in school absences No significant differences in ED use or emergency MD visits | |||
Mitchell et alw13 | Differences according to ethnicity of child No differences in hospital days | |||
Hughes et alw14 | Reduced school absences (P=0.04) | |||
McIntosh et alw15 | More treatment (35%) than control (17%) subjects reported more smoking outside their homes after test (and their children's cotinine levels were lower) but not significant | |||
Parcel et alw16 | Improved ED use but not significant Higher levels of self efficacy regarding asthma (P=0.018) | |||
Evans et alw17 | Increased self management (P=0.05) Increased communication with parent (P=0.002) Better academic grades (P=0.05) Fewer days with symptoms (P=0.004) | |||
Robinsonw18 | Reduced school absences (no statistical analysis) Better MDI technique (P=0.0005) Fewer hospital days (P=0.02) |
RCT=randomised controlled trial. ED=emergency department. MD=physician. MDI=metered dose inhaler.
Table B Studies evaluating adult education about asthma
Allen et alw19 | Increased knowledge (P<0.0001) Increased compliance (P<0.02) No difference in morbidity | |||
Bailey et alw20 | Better adherence to treatment regimens (P=0.0001) decreased ED visits and hospitalisations, but difference from control group not significant | |||
Bolton et alw21 | Fewer ED visits (most significant at 4 months P=0.003, but still at 12 months P=0.005) Reduction in ED charges by $628 | |||
Charlton et alw22 | Reduced median No of MD visits (from 8.0 to 2.0 in peak flow education group and 4.5 to 1.0 in symptoms only education group) Reduced use of oral corticosteroids | |||
Garrett et alw23 | Increased ownership of peak flow meters (P=0.0001) and improved technique (children P<0.05, adults P<0.005) Increased use of preventive drugs (adults P<0.05) Increased self management plans (adults P<0.01) Increased knowledge of action plan when symptoms worsened (children P<0.05, adults P<0.005) No difference in compliance, hospital admissions, ED use, or days lost from school or work | |||
Hilton et alw24 | Increased knowledge in maximum intervention group (P<0.05) No difference in self management ability or asthma morbidity | |||
Huss et alw25 | Greater adherence scores for avoidance measures (P<0.05) | |||
Jenkinson et alw1 | Increased knowledge of drugs (after 3 months P=0.002, after 12 months P=0.007) More significant increase in knowledge of intervention groups given tape than given only book (P=0.007) Reduction in perception of disability | |||
Kotses et alw26 | Reduced asthma attack frequency (P<0.05) Decreased use of drugs (cromolyn sodium P<0.01, 2 agonists P<0.05) Fewer asthma related problems ( P<0.01) | |||
Maiman et alw27 | Fewer ED visits (P=0.05 with intervention from asthmatic nurse, self identified or not) No significant results from booklet or non-asthmatic nurse plus booklet intervention | |||
Mayo et alw28 | In treated v untreated patients, threefold reduction in readmission rate (P<0.004), twofold reduction in hospital day use (P<0.05) In patients serving as their own controls, threefold reduction in readmission rate and hospital day use (P=0.003) | |||
Moldofsky et alw29 | No significant retention of knowledge No change in medical status | |||
Osman et alw30 | Fewer hospital admissions than control, by 54% (P<0.05) in those retained in clinic care and by 49% (95% CI 31% to 78%) in total intervention group Less sleep disturbance by 80% No significant difference in days of restricted activity, prescription of bronchodilators, inhaled corticosteroids, use of oral corticosteroids, No of MD consultants, or significant interaction between having a peak flow meter and education | |||
Ringsberg et alw31 | Decreased No of hospital days (P=0.0001) Reduced acute visits to hospital by 44% Increased knowledge No change in spirometric variables | |||
Snyder et alw32 | Increased knowledge (interaction effect, P<0.05) Decreased No of attacks (1.93 v 2.87 weekly, P<0.05) | |||
Yoon et alw33 | Fewer readmissions (educated group one seventh that of control, P<0.001) Decrease in ED visits (P<0.001) No difference in spirometric results, average PEF, or mean daily variability of PEF | |||
Wilson et alw34 | Reduced "bother" due to asthma (P<0.05) Increased physical activity (P<0.05) Improved asthma, judged by MD (P<0.05) Better environment control (P<0.0001) Improved MDI technique (P<0.05) | |||
Windsor et alw35 | Improvement in inhaler skills use (95% CI 0.29 to 0.61), inhaler adherence (0.24 to 0.50), drug adherence (0.31 to 0.57), and total adherence (0.28 to 0.56) Costs were $32.03/patient Cost effectiveness was $96.09 for intervention group and $243.68 for control group |
RCT=randomised controlled trial. ED=emergency department. MD=physician. MDI=metered dose inhaler.